NEW YORK STOCK EXCHANGE, INC. · LLY

+1.05% · +$12.38 · Vol Not reported

Pre-market · updated 05:34:04 ET

Eli Lilly and Co

Pharmaceuticals

$1,195

Card

Relationship Map

Follow $LLY

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $LLY by email

Veridion Score

BETAHIGH CONF · 6 of 6 factors measured

Mon Oct 12 · last completed session · Pre-market · regular session opens 9:30 ET · LLY

Methodology

LLY

Eli Lilly and Co

Mon Oct 12 · last completed session · Pre-market · regular session opens 9:30 ET

76/100

Highest qualified

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

76/ 100

Veridion Score

Highest qualified · HIGH confidence · 6 of 6 factors measured

Sovereign · $25/mo

See why this score moved.

· Factor breakdown with raw signals
· Day-over-day delta + driver
· Factor coverage readout
· Valuation · hype · market flow
· Pro Chart event markers
· Score history + alerts

Start Sovereign · $25/mo →or $250/yr

Cancel anytime · or Reserve · $79/mo or $790/yr

Confidence: HIGH · 6 of 6 factors measured · Mon Oct 12 · last completed session · Pre-market · regular session opens 9:30 ET

Share on X →

AI Analysis

Sovereign

Why is LLY moving today?

Sovereign unlock connects news, insider activity, analyst moves, and available price action.

Catalyst calendar

What can move LLY next.

Earnings, ratings, disclosures, volume, and score-history events. Every row needs a dated receipt.

Congress / Form 4 / Score

Upcoming

No dated upcoming catalyst is present in the current source window.

Recent

Oct 12
Score
Score moved +14
62/Upper range -> 76/Highest qualified
Veridion score historySource
Aug 18
Form 4
Jonsson Patrik Form 4 sale
SEC Form 4
Aug 11
Form 4
Zakrowski Donald A Form 4 sale
SEC Form 4
Aug 10
Form 4
Hakim Anat Form 4 sale
SEC Form 4
Jul 10
Congress
Dan Newhouse sale disclosed
STOCK Act filing
Jul 1
Congress
Michael A. Rulli sale disclosed
STOCK Act filing
Jun 10
Congress
Gilbert Ray Cisneros, Jr. purchase disclosed
STOCK Act filing
Apr 14
Congress
Gilbert Ray Cisneros, Jr. purchase disclosed
STOCK Act filing
Apr 8
Congress
Lizzie Fletcher sale disclosed
STOCK Act filing
Apr 2
Congress
Byron Donalds purchase disclosed
STOCK Act filing

About Eli Lilly and Co

PHARMACEUTICAL PREPARATIONS

Listed since

1970

Employees

50K

Country

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Company website →

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open

$1,182.62

Last session

Day high

$1,182.62

Last session

Day low

$1,182.62

Last session

Previous close

$1,182.62

52W high

$1,195

0.00% from high

52W low

$1,195

Market cap

$1.1T

P/E

41.59×

EPS

$29.80

Shares out

891.4M

VWAP

$1,182.62

Last session

LLY overview

Veridion Score

Registered · 2026-10-12

6 of 6 factors measured

Latest receipt rows

Not loaded

Disclosure read did not load.

13F holders

Not loaded

Relationship mapTrace receipt-backed holders and filings around LLY.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.

SEC Form 4 ledger

LLY insider activity

Eli Lilly and Co

90 days, by filing date. This issuer checked through Oct 12, 2026, 4:25 PM EDT. Published Oct 12, 2026, 4:32 PM EDT.

Score

76 · Highest qualified

Pressure

Net selling

Transactions

Filings

Buys / sells

0 / 3

Net value

-$16.0M

Insiders

Named filers

Jonsson Patrik

EVP & President, LLY Int'l

Officer

Zakrowski Donald A

SVP, Finance, & CAO

Officer

Hakim Anat

EVP, GC & Secretary

Officer

Cluster

No multi-insider purchase cluster in this filing window

Net pressure

Net selling: -$16.0M across loaded Form 4 rows.

Convergence not established

Loaded official disclosures do not show all three sources aligned on this ticker.

Showing 3 of 3 rows.

Scroll across filed transactions. Filing date stays visible.

Filing date	Trade date	Insider	Title	Type	Price	Qty	Owned	Value	Receipt
2026-08-18	2026-08-17	Jonsson Patrik	EVP & President, LLY Int'l	sell	$1,175.1	6,500	54,147	$7.6M	SEC Form 4
2026-08-11	2026-08-10	Zakrowski Donald A	SVP, Finance, & CAO	sell	$1,185.01	2,000	1,526	$2.4M	SEC Form 4
2026-08-10	2026-08-07	Hakim Anat	EVP, GC & Secretary	sell	$1,190	5,000	11,875	$6.0M	SEC Form 4

Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology

Public disclosures

Congress activity in LLY

Congress tracker Open ticker disclosure ledger →

Congress disclosures not loaded.

Federal contracts

LLY contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed

Refresh interval: 12hSource: Federal contract awards

No federal contracts on file for LLY in this window.

Lobbying spend

LLY lobbying filings, year to date.

Registered lobbying filings matched to Eli Lilly and Co.

$9.5M

Refresh interval: 12hSource: LDA disclosure filings

Health Issues Trade (domestic/foreign)Trade (domestic/foreign) Health Issues Medicare/Medicaid Consumer Issues/Safety/Products Copyright/Patent/Trademark Taxation/Internal Revenue Code PharmacyCopyright/Patent/Trademark Medicare/Medicaid Consumer Issues/Safety/Products Trade (domestic/foreign) Health Issues Taxation/Internal Revenue Code Pharmacy

Filing

$3.8M

ELI LILLY AND COMPANY

Apr 16, 2026

Filing

$3.3M

ELI LILLY AND COMPANY

Jul 16, 2026

Filing

$2.2M

ELI LILLY AND COMPANY

Jan 15, 2026